More about Health 2.0 Rasu Shrestha, CIO at the University of Pittsburg Medical Center, will be joining me on stage this afternoon in our Provider Symposium (on his birthday) and again on Tuesday, September 27th for our Information Blocking, APIs & App Stores: The State of Play in Data Access session. Below is the interview I had with him a couple of weeks ago about how a huge medical center like UPMC deals with the innovation side of the house. Not too late to sign up and come to Health 2.0 and come hear what else Rasu has to say!
Above the Fold
The Rise and Decline
of the Dartmouth Atlas
In my first comment in this series (an open letter to President Obama), I criticized Obama for stating in an article in the Journal of the American Medical Association that the Affordable Care Act is deflationary. I promised him I would post more essays showing how badly he had been misled by three experts who influenced him: Elliott Fisher and his colleagues at the Dartmouth Institute, Atul Gawande, and Peter Orszag.
My second post presented evidence that the research by Fisher et al. on regional variation in Medicare spending has been enormously influential with US policymakers for the last three decades.
In this comment, I demonstrate the gross inaccuracy of the Dartmouth group’s research.
Let me state at the outset: Even if every paper Fisher et al. wrote about regional variation in Medicare spending were true, none of them constituted evidence for the “accountable care organization.” In other words, even if we accept the Dartmouth group’s claim that regional and hospital variation is due primarily to overuse, we would still have no reason to accept the group’s claim that ACOs are the solution to all that overuse.Continue reading…
Practicing Physicians and Healthcare Reform: Population Health vs. Compensation Wealth
In her August 14th 2016 interview with the LA Times regarding the ACA and value-based reimbursement, HHS Secretary Sylvia Burwell stated, …”and medical providers want this.1” After reading this article, I wondered for a moment if I am working in the same healthcare system as the Secretary. Having spent a significant part of my 36-year career negotiating financial transactions with and/or on behalf of practicing physicians, I can unequivocally state that, unlike healthcare thought -leaders and policy wonks, a scant few practicing physicians are on board with population health management, value-based care and the “triple aim.”
It is essential to significantly improve the value of healthcare and it will require a lot of work by all. Given the disconnect between the policy makers/‘thought- leaders’ and the nation’s practicing physicians, I am pretty sure we are not going to get very far. Most practicing physicians consider the current movement to value based care/population health to be ineffective, expensive, bureaucratic interference with the practice of medicine.
A chat with Ian Morrison
My old friend and former boss Ian Morrison will be giving the keynote at Health 2.0’s 10th Annual Fall Conference on the afternoon of Tuesday, September 27th. Ian was President of Institute for the Future in the 1990s, founded the Strategic Health Perspectives service, and is in more health care board rooms and conference halls than almost anyone. At Health 2.0, Ian will share his latest insights into the future of health care. Did we tell you he’s the pre-eminent jokester on the health care speaking circuit? Well he is! You can still Register and come hear what else Ian has to say! But here’s a taster — Matthew Holt
For Healthcare Cybersecurity the Whole is Weaker Than the Sum of the Parts
Before addressing the special attractions and vulnerabilities of healthcare data and software, a little background on cybersecurity of complex systems may be helpful: The single most important lesson from our experiences with conventional networked systems is that all of them can be hacked, and all will eventually be hacked. There’s a simple equation for hackers: their investments are related to the value of the data. Alas, because electronic health records (EHRs) have a relatively high value to criminals, we should expect hackers to make significant efforts to penetrate EHRs. (More on this later.) Our experience also teaches us that erecting protections to mitigate hacking is never by itself an adequate defense. Instead, it is always necessary for health IT leaders to make significant efforts monitoring the EHR system for unanticipated behavior. Equally critical, it’s always necessary to plan how to respond to detected attacks.
Two mistakes: One of the biggest mistakes organizations make is failing to understand the threat; organizations typically are uninformed about the sophistication and resources of attackers, on one hand, and so underestimate their opponents, while on the other, they assume their systems are much less vulnerable than they actually are.
Rallying Cry: Cloud and Data First For Pharma
Maybe it is just the shock of being post Labor Day and realizing that summer is fading into the rear view mirror or maybe it was something I ate for breakfast that spurred new hope. But I think that this is the year that the patient centric approach to data in life sciences finally takes off. And along with that launch will come the massive rapid migration to cloud and data lake architectures for pharma data.
Really? Why now you may ask?
Yeah – that’s right. Every group I have been talking to is worried that they are sitting atop a jigsaw puzzle of siloed data resources that can’t be assembled fast enough to meet the needs of business and scientific users. Organizations are thinking that they can’t answer their questions about why drugs work in some patients and not others if they can’t link phenotype and genotype data. Groups can’t look across clinical trials. They can’t look beyond and between clinical trials and EMR data. Progressive safety groups are considering using automation and cognitive computing to lower costs in processing events so they can then look in parallel to expanding sensing new signals into 10X current volumes of data within large real world data sets.Continue reading…
A Fail For Activity Trackers: The I Told You So’s vs Need More Datas
Perhaps the normally measured physician-economist Aaron Carroll best captured the reaction and sentiments of the healthcare community in response to a recent JAMA article demonstrating that subjects in a weight reduction study using activity trackers lost significantly less weight than those in the control group:
“I TOLD YOU SO!!!!!!” (Emphasis in original.)
These results were cheered for several key reasons.
First, many in healthcare are irritated by the idea of simplistic technical fixes for complex medical (and social) (and cultural) (and economic) problems–like obesity.
Second, as Carroll has pointed out, exercise is healthy for many reasons, but weight loss is probably not one of them; changing your diet seems to matter a lot more.
However, it’s important to critically evaluate research even (especially) when it seems to produce an ego-syntonic conclusion–a conclusion with which we so strongly agree.
My initial reaction to the result was that perhaps it reflects an example of the concept of “moral licensing” that Malcolm Gladwell discusses so thoughtfully on his Revisionist History podcast–i.e., when you deliberately act morally in one context, you may be more likely to act less morally in another context, having already demonstrated to yourself your moral bona fides.
So, Do Transparency Tools Actually Work?
A new report by economist Jon Gabel and his colleagues at NORC, a research center affiliated with the University of Chicago, looked at the use of transparency tools in an employer health plan. The analysis found the use of price transparency tools to be spotty. For instance, 75 percent of households either did not log into the transparency tool or did so only one time in the 18-month period of study. Fifteen percent did so twice; but only 1 percent logged in 6 times or more. The authors concluded:
It could very well be that we are asking too much of a single tool, no matter how well-designed. Consumer information for other goods and services on price and quality are seldom dependent upon information gained mainly, if not solely, through a digital tool. Rather, information on relative value is spread far and wide through advertising and other kinds of promotion using conventional, digital, and social media communication channels.
An earlier Harvard study on transparency tools, published in JAMA, found patients do not tend to use the tools to comparison shop for lower prices (in fact, spending rose slightly). An NBER study concluded that when transparency tools do lower spending, it is because consumers used to tools to identify prices and use the information to decide whether they can afford the service and skip it if they cannot.
The transparency tool in the current study also emailed “Ways to Save” suggestions on how consumers could reduce medical spending. The authors made an important observation:
It is also possible that the message on the “Ways to Save” e-mail turned off many households. While the emails did highlight opportunities to save a specific amount of money, a vast majority of the savings were for the employer and a much smaller amount of savings applied to the employee. It is possible that many employees viewed the transparency initiative as simply a means for the employer to save money.
The Nordics at Health 2.0
By now you all know that the 10th Annual Health 2.0 Fall Conference is next week. What you may not know is that it’s a great place to meet delegates from across the world. In particular both tech companies and providers & government officials from from Scandinavia will be there next week. Below are Ase Bailey (TINC in Silicon Valley/Innovation Norway) & Anne Lidgard (VINNOVA/Innovation Sweden) talking about the Nordic group’s visit to Health 2.0. By the way, for those in the Bay Area, there’s a reception with the Nordic delegation at the Nordic House in Palo Alto on Thursday night — Matthew Holt
Statin Wars: Less-is-More versus Unlimited Medicine
It is the beauty of evidence-based medicine (EBM) that a scientist can at once be a Pope and a Galileo. His transmutation is as effortless as it is discretionary. If you think you’ve met Galileo – a rebel, a free thinker, a rocker of the establishment – the following week he is a Pope, castigating detractors, censoring critics, and celebrating uniformity. He changes by a roll of the dice. His change is decided by a quirk in hypothesis-testing known as statistical significance. If the p value is 0.051 he is Galileo, if the p value is 0.049 he becomes the cardinal. He is one day a raging skeptic and another day a true believer.
The latest fight between orthodoxy and free inquiry is about the benefits and harms of statins for primary prevention. A review, and an editorial, in the Lancet said the benefits of statins are real, the harms are exaggerated, and skepticism of benefits of statins should be censored because doubt can harm the public who may not take their statins and thus die prematurely. Stated differently, skepticism kills. The lead author of the review once asked the BMJ to retract a study which he felt overplayed the harms and denied the benefits of statins. The editor compared the fear about statins to fear about vaccination. Statin skeptics, like vaccine deniers, are now medicine’s truthers.
